Team Amipem, UMR MICALIS
The importance of the intestinal microbiota for the physiology of the host and its involvement in the development of physio-pathological phenomena are increasingly recognised. In this context, our research focuses on the study of the gut microbiota-food interaction as a factor of vulnerability to the development of human pathologies.
Our studies therefore lie at the interface between microbiology, nutrition and physiopathology, and mainly use preclinical models, including microbiota transplants to germfree or specific-pathogen free rodents. Pathologies we consider include psychiatric diseases (anxiety and depression, autism, eating disorders…), metabolic diseases (obesity, diabetes, liver diseases) as well as colon cancer, atherosclerosis.
Last publications
-
-
-
Magali Monnoye, Pauline Flauss, Catherine Philippe, Nathalie Castanon, Sylvie Rabot, et al.. Modulation of gut microbiota by antibiotics did not affect anhedonia in a high-fat diet-induced model of depression in male mice. Journal of Food, Nutrition and Diet Science, 2023, 1 (1), pp.20-32. ⟨10.55976//fnds.12023117220-32⟩. ⟨hal-04189068⟩
-
Florian Plaza Oñate, Célia Chamignon, Sebastian Burz, Nicolas Lapaque, Magali Monnoye, et al.. Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease. International Journal of Molecular Sciences, 2023, 24 (15), pp.12232. ⟨10.3390/ijms241512232⟩. ⟨hal-04214482⟩
-
Laurent Ferraris, Aurélie Balvay, Deborah Bellet, Johanne Delannoy, Claire Maudet, et al.. Neonatal necrotizing enterocolitis: Clostridium butyricum and Clostridium neonatale fermentation metabolism and enteropathogenicity. Gut microbes, 2023, 15 (1), pp.2172666. ⟨10.1080/19490976.2023.2172666⟩. ⟨hal-04106612⟩